Jacob A. Troutman
Experienced in Neuroblastoma

Dr. Jacob A. Troutman

Hematology | Oncology
Lehigh Valley Health Network
LVPG Pediatric Hematology Oncology-Cedar Crest
1210 S Cedar Crest Blvd., Suite 1000, 
Allentown, PA 
17 Years of Experience

Experienced in Neuroblastoma
Lehigh Valley Health Network
LVPG Pediatric Hematology Oncology-Cedar Crest
1210 S Cedar Crest Blvd., Suite 1000, 
Allentown, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Philosophy of care | I believe children are a unique population of patients that require a physician dedicated to their well-being. I believe they are vulnerable and often unable to speak up for themselves. I believe that each child and family should be treated as if they are my own relation. | Why I entered medicine | I entered medicine for the satisfaction of being able to help and offer hope to those who are ill. I chose pediatric hematology oncology because these children have a serious illness and their parents are at the lowest point of their lives, and I can provide them with hope and compassion. | Community involvement | I volunteer at Camp Dost, a camp for children with cancer. Since 2003 I have helped there, and love seeing how this experience helps kids who are dealing with cancer enjoy time just being kids. | Personal interests | I enjoy many types of sports, but specifically like basketball, baseball, football, and golf. I also like to go canoeing and doing physical fitness activities.

Dr. Troutman is rated as an Experienced provider by MediFind in the treatment of Neuroblastoma. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Sickle Cell Disease, Thalassemia, and Hemoglobin SC Disease.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 6 clinical trials in the study of Neuroblastoma.

Graduate Institution
University Of New England College Of Osteopathic Medicine, Doctor Of Osteopathic Medicine (DO), 2009, 2009
Residency
Pediatrics, Geisinger Medical Center GME, Danville, PA- 2012
Specialties
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in PA
Board Certifications
American Board Of Pediatrics - Pediatric Hematology-Oncology
American Board Of Pediatrics - Pediatrics
Fellowships
Pediatric Hematology-Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC- 2015
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
View 12 Less Insurance Carriers -

Locations

LVPG Pediatric Hematology Oncology-Cedar Crest
1210 S Cedar Crest Blvd., Suite 1000, Allentown, PA 18103
Call: 610-402-1026
Other Locations
LVPG Pediatric Hematology Oncology-Pennsburg
101 W 7th Street, Suite 2C, Pennsburg, PA 18073
Call: 484-763-5275

Additional Areas of Focus

Dr. Troutman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


17 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Larotrectinib Sulfate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
A Phase I/II Study of Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Study ITCC-054/COG-AAML1921
A Phase I/II Study of Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Study ITCC-054/COG-AAML1921
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Drug
Study Drug: Bosutinib
Study Phase: Phase 1/Phase 2
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
View 16 Less Clinical Trials

2 Total Publications

Ewing Sarcoma of the 9th Rib Subsequent to Pediatric Leukemia: A Case Series.
Ewing Sarcoma of the 9th Rib Subsequent to Pediatric Leukemia: A Case Series.
Journal: Journal of pediatric hematology/oncology
Published: February 23, 2021
View All 2 Publications
Similar Doctors
Elite in Neuroblastoma
Dr. Kristopher R. Bosse
Pediatrics | Hematology | Oncology
Elite in Neuroblastoma
Dr. Kristopher R. Bosse
Pediatrics | Hematology | Oncology
34th St. & Civic Center Blvd, The Children's Hospital Of Philadelphia, Room 9nw55, 
Philadelphia, PA 
 (49.4 miles away)
215-590-2437
Languages Spoken:
English
See accepted insurances

Kristopher Bosse is a Pediatrics specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Bosse is rated as a Distinguished provider by MediFind in the treatment of Neuroblastoma. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Adrenal Cancer.

Nehal S. Parikh
Advanced in Neuroblastoma
Dr. Nehal S. Parikh
Hematology | Oncology
Advanced in Neuroblastoma
Dr. Nehal S. Parikh
Hematology | Oncology

LVPG Pediatric Hematology Oncology-Cedar Crest

1210 S Cedar Crest Blvd., Suite 1000, 
Allentown, PA 
 (8.1 miles away)
610-402-1026
Languages Spoken:
English
See accepted insurances

Philosophy of care | I believe in a care team that embraces partnership with patients and families to deliver effective, first-class medical treatment. I value and incorporate suggestions provided by my patients and families to optimize my approach to their care. | Why I entered medicine | I entered medicine because of my interest in science and being able to care for patients. | Community involvement | I provide mentorship to local students and package donated goods for the armed forces. | Personal interests | Skiing. Dr. Parikh is rated as an Advanced provider by MediFind in the treatment of Neuroblastoma. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Sickle Cell Disease, and Immune Thrombocytopenic Purpura (ITP).

Satish Singla
Advanced in Neuroblastoma
Dr. Satish Singla
Hematology | Oncology
Advanced in Neuroblastoma
Dr. Satish Singla
Hematology | Oncology

Satish Singla, MD

700 Schuylkill Manor Road, 
Pottsville, PA 
 (41.1 miles away)
570-622-4113
Languages Spoken:
English
See accepted insurances

Satish Singla is a Hematologist and an Oncologist in Pottsville, Pennsylvania. Dr. Singla is rated as a Distinguished provider by MediFind in the treatment of Neuroblastoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Laryngeal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration.

VIEW MORE NEUROBLASTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Troutman's expertise for a condition
ConditionClose
      • Advanced
      • Acute Lymphoblastic Leukemia (ALL)
        Dr. Troutman is
        Advanced
        . Learn about Acute Lymphoblastic Leukemia (ALL).
        See more Acute Lymphoblastic Leukemia (ALL) experts
      • Hemoglobin SC Disease
        Dr. Troutman is
        Advanced
        . Learn about Hemoglobin SC Disease.
        See more Hemoglobin SC Disease experts
      • Sickle Cell Disease
        Dr. Troutman is
        Advanced
        . Learn about Sickle Cell Disease.
        See more Sickle Cell Disease experts
      • Thalassemia
        Dr. Troutman is
        Advanced
        . Learn about Thalassemia.
        See more Thalassemia experts
      • Experienced
      • Adult Soft Tissue Sarcoma
        Dr. Troutman is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Alpha Thalassemia
        Dr. Troutman is
        Experienced
        . Learn about Alpha Thalassemia.
        See more Alpha Thalassemia experts
      • Beta Thalassemia
        Dr. Troutman is
        Experienced
        . Learn about Beta Thalassemia.
        See more Beta Thalassemia experts
      • Cantu Syndrome
        Dr. Troutman is
        Experienced
        . Learn about Cantu Syndrome.
        See more Cantu Syndrome experts
      • Classical Hodgkin Lymphoma
        Dr. Troutman is
        Experienced
        . Learn about Classical Hodgkin Lymphoma.
        See more Classical Hodgkin Lymphoma experts
      • Congenital Hemolytic Anemia
        Dr. Troutman is
        Experienced
        . Learn about Congenital Hemolytic Anemia.
        See more Congenital Hemolytic Anemia experts
      View All 39 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved

        Request an Appointment

        If you are experiencing a medical emergency, call 9-1-1.

        MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

        Patient Details

        This information is for the patient who will be seen at the appointment.

          Close

          Returning patient? Use your address on file with the provider.

          Insurance Details

          Please provide information of the primary insurance holder as the practice may require this information to schedule.

          Insurance Provider *
          Insurance ProviderClose

          Appointments Details

          Let’s get more information about your appointment.

                  0 / 1000
                  0 / 1000
                  By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.